(NASDAQ: CDXC) Chromadex's forecast annual revenue growth rate of 8.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.49%, and while it is forecast to beat the US market's average forecast revenue growth rate of 6.64%.
Chromadex's revenue in 2023 is $83,370,000.On average, 3 Wall Street analysts forecast CDXC's revenue for 2023 to be $6,253,807,301, with the lowest CDXC revenue forecast at $6,212,789,369, and the highest CDXC revenue forecast at $6,287,913,787. On average, 3 Wall Street analysts forecast CDXC's revenue for 2024 to be $7,301,041,688, with the lowest CDXC revenue forecast at $7,136,819,710, and the highest CDXC revenue forecast at $7,399,755,173.
In 2025, CDXC is forecast to generate $8,729,457,372 in revenue, with the lowest revenue forecast at $8,729,457,372 and the highest revenue forecast at $8,729,457,372.